Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Neurocrine Biosciences, Inc.”

110 pharma patents match "Neurocrine Biosciences, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 110
Index total 30,257
Page 1 / 5

Quick answer

This filtered view shows 110 pharmaceutical patents matching "Neurocrine Biosciences, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

110 results for “Neurocrine Biosciences, Inc.” · 30,257 patents in full index Clear search

  1. US 12421193

    GPR52 modulators and methods of use

    Neurocrine Biosciences, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  2. US 12383536

    CRF receptor antagonists and methods of use

    Neurocrine Biosciences, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  3. US 12128033

    Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

    Neurocrine Biosciences, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  4. US 12102637

    Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Neurocrine Biosciences, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  5. US 12083227

    Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Neurocrine Biosciences, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  6. US 11730739

    Treatment of congenital adrenal hyperplasia

    Neurocrine Biosciences, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  7. US 11718618

    Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted
  8. US 11713324

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  9. US 11654142

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  10. US 11459305

    Processes for the preparation of uracil derivatives

    Neurocrine Biosciences, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  11. US 11439629

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  12. US 11311532

    High dosage valbenazine formulation and compositions, methods, and kits related thereto

    Neurocrine Biosciences, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  13. US 11311544

    Treatment of congenital adrenal hyperplasia

    Neurocrine Biosciences, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  14. US 11053242

    [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  15. US 11040029

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  16. US 11040970

    VMAT2 inhibitor compounds and compositions thereof

    Neurocrine Biosciences, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  17. US 11033539

    Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases

    Neurocrine Biosciences, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  18. US 11026931

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  19. US 11026939

    High dosage valbenazine formulation and compositions, methods, and kits related thereto

    Neurocrine Biosciences, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  20. US 11021449

    Substituted triazoles and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  21. US 10993941

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  22. US 10952997

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  23. US 10941159

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  24. US 10940141

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted